Input Parameter Values, by Patient Subgroup and Treatment Regimen.^a

HCV indicates hepatitis C virus; N/A, not applicable; PR, peginterferon alfa-2a plus ribavirin; SVR, sustained virologic response; TVR, telaprevir. aAll parameter estimates are derived from ADVANCE and REALIZE [13], [14], [15] (Vertex Pharmaceuticals, unpublished data, 2011). bFibrosis score distributions reflect the combined patient populations of 12-week TVR+PR and PR-alone treatment arms of the clinical trials. Values in each column do not sum to 100% due to rounding; actual values sum to 100%. cData from ADVANCE and REALIZE were available for patients with baseline fibrosis scores F0 and F1 combined. The model assumed half had baseline fibrosis score F0 and half had baseline fibrosis score F1. dThe model included severe treatment-related adverse events that occurred in 2% or more of patients in at least one treatment arm of ADVANCE and REALIZE. Incidence of anemia included moderately severe cases. From REALIZE, data were available for all previously treated patients combined. eSee Table S2 in Appendix S1 for utility scores from ADVANCE and REALIZE, from which average utility values were calculated.